Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib vs Standard Treatment in Advanced MET Exon 14 Mutated NSCLC
NCT06908993Phase 3Recruiting
- Sponsor
- IFCT
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by IFCT. Started Dec 2025; status: recruiting.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06908993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908993.